Novartis AG ADR (NVS)vsPersonalis Inc (PSNL)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
PSNL
Personalis Inc
$5.04
-8.36%
HEALTHCARE · Cap: $575.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 81272% more annual revenue ($56.67B vs $69.65M). NVS leads profitability with a 24.7% profit margin vs -116.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PSNL
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Margin of Safety
-51.4%
Fair Value
$5.88
Current Price
$5.04
$0.84 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
3.2% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -35.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : PSNL
The strongest argument for PSNL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : PSNL
The primary concerns for PSNL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a value stock while PSNL is a turnaround play — different risk/reward profiles.
PSNL carries more volatility with a beta of 2.21 — expect wider price swings.
PSNL is growing revenue faster at 3.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Personalis Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?